Oh yeah, and this too:
Sorry, looks like GSK is passing on the California wine for the Swiss cheese. ;-)
GlaxoSmithKline Buys Remaining Shares in GlycoVaxyn for $190M
3:18a ET February 11, 2015 (Dow Jones) Print
GlaxoSmithKline Buys Remaining Shares in GlycoVaxyn for $190M
By Ian Walker
LONDON--Pharmaceutical giant GlaxoSmithKline PLC (GSK.LN) said Wednesday it has bought the remainder of Swiss specialist vaccine biopharmaceutical company GlycoVaxyn for $190 million, giving it full control.
Glaxo has held a minority stake in GlycoVaxyn since forming a scientific collaboration in 2012. It didn't disclose how much it already held. However, based on the offer price, GlycoVaxyn is valued at $212 million, which would indicate a shareholding of about 10%.
As part of the deal, Glaxo will buy a small number of early stage vaccines in development against bacterial infections such as pneumonia, Pseudomonas, Staphylococcus aureus and Shigellosis, supplementing its existing vaccines pipeline.
Now ya' knows, ya' knows, ya knows......
Dance Biopharm Appoints Dr. Tyler Martin to the Position of President and Director
9:00a ET February 11, 2015 (PR NewsWire) Print
Dance Biopharm Inc. (Dance), a privately-held biotechnology company focused on the development of inhaled insulin products to treat diabetes, today announced the appointment of J. Tyler Martin, M.D., to the newly created position of president. Dr. Martin has also been appointed to the board of directors. He brings more than 20 years of experience in the biotechnology industry to Dance, where he oversees company operations, reporting to Dr. John Patton, CEO.
If not "headwinds", then very likely a vaccine panel "head" or two......
What year was all of that from? ;-)
My article came from "today" by "Mostly Gruel" publications.
But I would be willing to bet hard currency that the Earle of thievery won't even bother to pick up the phone and try to call Pfizer........
Deal-Hungry Pfizer Won't Stop With Hospira; Who Could Be Next?
By Cheryl Swanson
February 16, 2015
Pfizer (NYSE: PFE ) finally got its sweet deal!
After being spurned repeatedly by British drugmaker AstraZeneca, Pfizer recently anted up $17 billion for a much smaller drug company, Hospira (NYSE: HSP ) . The deal represents a hefty 39% premium over the Illinois-based company's previous day close, but Pfizer's investors immediately applauded, tacking $6 billion onto Pfizer's market value the day after the deal was announced.
While the acquisition surprised almost everyone, I think it's a savvy move. Hospira will allow Pfizer to beef up its established products business, which has been on a downward trajectory, declining 9% year over year last year to $25 billion. The Hospira acquisition should boost that unit by $4 billion, making it the largest one by revenue, which could position it for a possible spinoff.
With Hospira, Pfizer is also tapping into biosimilars -- one of the most exciting new markets for drugmakers in the U.S. Biosimilars are lower-price knockoffs of costly biologic drugs that have been immune from competition in the United States.
All that could be changing. Biosimilars have long been available in Europe, and the FDA is on the cusp of approving them in the United States. Recently, an advisory panel to the FDA recommended approval of a biosimilar of the blockbuster Amgen drug Neupogen. If the agency gives the drug the go-ahead, it will be the first biosimilar in the U.S. and will pave the way for more of these drugs to enter the marketplace.
Hospira is already one of the largest providers of biosimilars in Europe. According to the The Wall Street Journal, adding Hospira's ready-made lineup of biosimilars to its pipeline should transform Pfizer into a leading player in bios
I'll give ya' A+ on that one, and I'm not even a short.
Back in November of 2012 it was certainly the shorts that took the shellacing; now wasn't it?
But, yet, if they took the hit, why did I get the honor of watching 20-30% of my long position melt away?
I'm sure that Fair Issac / Green Mountain knows the truth, but like many others here, he prefers the taste of the sand, so that is where he chooses to keep his head buried.
A+ to you, indeed, there Ctic.
Now, on with giving away the options freebies! Let them ALL eat cake!
They're NEVER the same. You people never want to say it's the same.
You NEVER want to compare them on an even roughly equivalent basis.
But don't you want them to be viewed and considered the same on the STOCK MARKET??? Of course you do.
You don't want you puny, little, crummy stock looking like it has to ride the short bus and go to the "special" school.
But yet, when it comes to a critical eye, it's "Oh, that's not the same, they're not the same stock."
Rubbish. What rubbish, rubbish, rubbish.
"First, we pay OURSELVES."
1. Pursuant to the Dynavax 2004 Non-Employee Director Option Program and the 2005 Non-Employee Director Cash Compensation Program, as amended (the "Directors' Plan"), Ms. Brege was granted an initial non-qualified stock option to purchase 2,000 shares of Dynavax common stock, with an exercise price equal to the fair market value on the date of grant, vesting over four years in equal annual installments;
2. Pursuant to the Directors' Plan, Ms. Brege will be eligible to receive a non-qualified option to purchase up to an additional 7,500 shares of Dynavax common stock immediately following each annual meeting of Dynavax's stockholders (with respect to the first such grant, the option will be pro-rated in accordance with the terms of the Directors' Plan), with an exercise price equal to the fair market value on the date of grant, vesting on the first anniversary of the grant; and
3. Pursuant to the Directors' Plan, Ms. Brege will receive an annual retainer of $40,000 as a member of the Board of Directors and $20,000 as Chairman of the Audit Committee, payable in equal quarterly installments in arrears.
A copy of the press release relating to Ms. Brege's appointment is attached hereto as Exhibit 99.1.
(e) Compensation Arrangements of Certain Officers and Directors
On February 5, 2015, upon the recommendation of the Compensation Committee, the Board approved 2015 base salaries and 2014 bonuses for the executive officers of the Company, including the named executive officers. The Board delegated approval of 2015 equity awards to the Compensation Committee. On February 9, 2015, the Compensation Committee approved equity awards for the named executive officers, composed of options with an exercise price equal to the fair market value on the date of grant, one half of which would be contingent on stockholder approval of an increase in the number of shares available under the 2011 Equity Incentive Plan.
The REAL question would be "what would YOU lose?"
Ole' studvooh had better watch out.
Looks like your bucking for #1 DVAX cheerleader with all the answers.
You win the prize and take the cake......
Sounds like you and your merry band of cheerleaders have this news all sewn up!
OK, when's the buyout? Oh, you DO realize that giving away mucho free bonuses like this HAS to mean buyout; don't you?
Feel free to talk amongst yourselves.......
No, nooooooooo. I just CAN'T imagine ANY small biotech doing something like that.
(Hint: I'm sure it's happened NUMEROUS times before :-p )
RAD is actually buying some company and their forward projections look good after they swallow this acquisition!
Remember, you heard it here first! From ME that is; that rad was and IS a good company and stock to trade and invest in.
Check it folks, what has DVAX bought lately? Has ANYONE bought DVAX lately? You KNOW the answers to those. Leave this stick in the mud where it is and do something better for yourselves. Go with RAD, it's cheaper and they have lots and LOTS of things to sale and make sales!
Remember, you heard it from the black birdie first! :-D
Oh, BRAVO, Ctic!
That was, "masterpiece-like"
I know you'll be in trouble because of my association to your post; but I'll risk it.
"DVAX to the moon!"
BTW, Jack will be here in 5 minutes to provide management's view on all of this.......
You should wish that there WERE a 33% holder.
Another 20% addition from there and this junky little company would be bought out.
But, nope, you said it yourself, NOBODY ANYWHERE wants to own that much of this little train wreck.
At least you're being honest; I appreciate that. And truth about the situation is a step in the right direction for you. :-)
Because OJ is a "good company man".
The company could come out and make an obvious and blatant screw to the company shareholders and Jack would turn up 30 minutes later and tell the shareholders why it's good for them AND good for the company.
In fact, I think he did so before during the run up to the RS.
He's a "company man"; he never leave them and he'll never turn against them, no matter how bad this thing turns.
When he speaks, it's almost like getting a PR from Ostrachi himself. ;-)
Pfizer buys Hospira for $15-$16BB.
Something like, $90 per share of Hospira?
Gee now, how could PFE have passed on ole' D-V-A-X???
All that money to spend and they could have had Earle's baby for virtually, a song.
Yet, they passed. They passed, they PASSED on buying your little diamond company.
HOW COULD THAT BE?
Here we are in a new year and yet it's the same old song and dance for this sad little company.
NO ONE wants it. Why? Why, why, Y????
(I wouldn't be surprised if you STILL refuse to see "it" yet)
I also mentioned PACB here. Same thing, people chipped their teeth at me in complaint.
In January, PACB was up to the $8-$9 range, but today seems to be down on an earnings miss.
They too, have products to sell. High technology products, to be exact.
The whole point to my "recommendations" were that there are MANY better places to invest in the US equities markets than this sorry toad of a company and stock.
I also mentioned RAD here. Got pu-pu'ed about that one.
Today, RAD is back to $7-$7.5 per share and just showed +5% increase in same store sales for January.
Newsflash, RAD also has more products to sell than DVAX.